U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H11NO4
Molecular Weight 197.1879
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVODOPA

SMILES

N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O

InChI

InChIKey=WTDRDQBEARUVNC-LURJTMIESA-N
InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1

HIDE SMILES / InChI

Molecular Formula C9H11NO4
Molecular Weight 197.1879
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23948989 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021485s20lbl.pdf

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been widely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

Originator

Curator's Comment: # Hoffmann-La Roche

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Stalevo

Approved Use

Stalevo® (carbidopa, levodopa and entacapone) is indicated to treat patients with idiopathic Parkinson’s disease.

Launch Date

1.0552032E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.946 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered: CARBIDOPA, DL-
LEVODOPA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
84.8 μg × min/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered: CARBIDOPA, DL-
LEVODOPA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
78.7 min
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered: CARBIDOPA, DL-
LEVODOPA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
80%
LEVODOPA plasma
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
3 g 1 times / day multiple, oral
Dose: 3 g, 1 times / day
Route: oral
Route: multiple
Dose: 3 g, 1 times / day
Sources:
unhealthy, 54 years
n = 1
Health Status: unhealthy
Condition: idiopathic Parkinson's disease
Age Group: 54 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Alopecia...
AEs leading to
discontinuation/dose reduction:
Alopecia (1 patient)
Sources:
420 mg 1 times / day multiple, respiratory
Recommended
Dose: 420 mg, 1 times / day
Route: respiratory
Route: multiple
Dose: 420 mg, 1 times / day
Sources:
unhealthy, adult
84 mg 2 times / day multiple, respiratory
Recommended
Dose: 84 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 84 mg, 2 times / day
Sources:
unhealthy, adult
n = 114
Health Status: unhealthy
Condition: Parkinson’s disease
Age Group: adult
Population Size: 114
Sources:
Disc. AE: Cough...
AEs leading to
discontinuation/dose reduction:
Cough (2%)
Sources:
0.51 mg/kg 3 times / day steady, oral
Dose: 0.51 mg/kg, 3 times / day
Route: oral
Route: steady
Dose: 0.51 mg/kg, 3 times / day
Sources:
unhealthy, child|adult
n = 15
Health Status: unhealthy
Condition: Vision Impairment
Age Group: child|adult
Population Size: 15
Sources:
Other AEs: Headache, Nausea...
Other AEs:
Headache (below serious, 2 patients)
Nausea (below serious, 2 patients)
Sources:
0.76 mg/kg 3 times / day steady, oral
Dose: 0.76 mg/kg, 3 times / day
Route: oral
Route: steady
Dose: 0.76 mg/kg, 3 times / day
Sources:
unhealthy, child|adult
n = 15
Health Status: unhealthy
Condition: Vision Impairment
Age Group: child|adult
Population Size: 15
Sources:
Other AEs: Headache, Dry mouth...
Other AEs:
Headache (below serious, 1 patient)
Dry mouth (below serious, 2 patients)
Nausea (below serious, 1 patient)
Fatigue (below serious, 2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Alopecia 1 patient
Disc. AE
3 g 1 times / day multiple, oral
Dose: 3 g, 1 times / day
Route: oral
Route: multiple
Dose: 3 g, 1 times / day
Sources:
unhealthy, 54 years
n = 1
Health Status: unhealthy
Condition: idiopathic Parkinson's disease
Age Group: 54 years
Sex: F
Population Size: 1
Sources:
Cough 2%
Disc. AE
84 mg 2 times / day multiple, respiratory
Recommended
Dose: 84 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 84 mg, 2 times / day
Sources:
unhealthy, adult
n = 114
Health Status: unhealthy
Condition: Parkinson’s disease
Age Group: adult
Population Size: 114
Sources:
Headache below serious, 2 patients
0.51 mg/kg 3 times / day steady, oral
Dose: 0.51 mg/kg, 3 times / day
Route: oral
Route: steady
Dose: 0.51 mg/kg, 3 times / day
Sources:
unhealthy, child|adult
n = 15
Health Status: unhealthy
Condition: Vision Impairment
Age Group: child|adult
Population Size: 15
Sources:
Nausea below serious, 2 patients
0.51 mg/kg 3 times / day steady, oral
Dose: 0.51 mg/kg, 3 times / day
Route: oral
Route: steady
Dose: 0.51 mg/kg, 3 times / day
Sources:
unhealthy, child|adult
n = 15
Health Status: unhealthy
Condition: Vision Impairment
Age Group: child|adult
Population Size: 15
Sources:
Headache below serious, 1 patient
0.76 mg/kg 3 times / day steady, oral
Dose: 0.76 mg/kg, 3 times / day
Route: oral
Route: steady
Dose: 0.76 mg/kg, 3 times / day
Sources:
unhealthy, child|adult
n = 15
Health Status: unhealthy
Condition: Vision Impairment
Age Group: child|adult
Population Size: 15
Sources:
Nausea below serious, 1 patient
0.76 mg/kg 3 times / day steady, oral
Dose: 0.76 mg/kg, 3 times / day
Route: oral
Route: steady
Dose: 0.76 mg/kg, 3 times / day
Sources:
unhealthy, child|adult
n = 15
Health Status: unhealthy
Condition: Vision Impairment
Age Group: child|adult
Population Size: 15
Sources:
Dry mouth below serious, 2 patients
0.76 mg/kg 3 times / day steady, oral
Dose: 0.76 mg/kg, 3 times / day
Route: oral
Route: steady
Dose: 0.76 mg/kg, 3 times / day
Sources:
unhealthy, child|adult
n = 15
Health Status: unhealthy
Condition: Vision Impairment
Age Group: child|adult
Population Size: 15
Sources:
Fatigue below serious, 2 patients
0.76 mg/kg 3 times / day steady, oral
Dose: 0.76 mg/kg, 3 times / day
Route: oral
Route: steady
Dose: 0.76 mg/kg, 3 times / day
Sources:
unhealthy, child|adult
n = 15
Health Status: unhealthy
Condition: Vision Impairment
Age Group: child|adult
Population Size: 15
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.
1975 Apr
The effects of combining carbidopa with levodopa for Parkinson's disease.
1975 Dec
A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease.
1999 Apr
[A case of primary brain-stem injury recovered from persistent vegetative state after L-dopa administration].
1999 Dec
Risk factors for levodopa-induced dyskinesias in Parkinson's disease.
1999 Dec
Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study.
1999 Jul 13
Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations.
1999 Jul-Aug
Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
1999 Nov
[Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
2000
Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia.
2000
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
2000 Apr
L-Dopa uptake and dopamine production in proximal tubular cells are regulated by beta(2)-adrenergic receptors.
2000 Jul
The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.
2000 Mar-Apr
Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?
2000 May
Detection and assessment of the severity of levodopa-induced dyskinesia in patients with Parkinson's disease by neural networks.
2000 Nov
SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats.
2001 Aug
Dopamine D(2) receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum.
2001 Feb
Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's disease.
2001 Jan
Enhanced abilities of highly swollen chitosan beads for color removal and tyrosinase immobilization.
2001 Jan 29
Biogenic aldehyde(s) derived from the action of monoamine oxidase may mediate the antidipsotropic effect of daidzin.
2001 Jan 30
Effects of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) on alpha2-adrenoceptors which regulate the synthesis and release of noradrenaline in the rat brain.
2001 Mar
Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa.
2001 Mar
Levodopa-induced drowsiness in healthy volunteers: results of a choice reaction time test combined with a subjective evaluation of sedation.
2001 Mar-Apr
Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions.
2008 Dec 3
Patents

Sample Use Guides

Maximum dosage in a 24-hour period is eight tablets (Stalevo 50, containing 12.5 mg of carbidopa, 50 mg of levodopa and 200 mg of entacapone; Stalevo 75, containing 18.75 mg of carbidopa, 75 mg of levodopa and 200 mg of entacapone; Stalevo 100, containing 25 mg of carbidopa, 100 mg of levodopa and 200 mg of entacapone; Stalevo 125, containing 31.25 mg of carbidopa, 125 mg of levodopa and 200 mg of entacapone; Stalevo 150, containing 37.5 mg of carbidopa, 150 mg of levodopa and 200 mg of entacapone; Stalevo 200, containing 50 mg of carbidopa, 200 mg of levodopa and 200 mg of entacapone). The optimum daily dosage must be determined by careful titration in each patient.
Route of Administration: Oral
Low dose (<30 uM) Levodopa protects PC12 cells against oxidative stress which might be related to the up-regulation of CD39 and pCREB expression.
Substance Class Chemical
Created
by admin
on Sun Dec 18 19:39:25 UTC 2022
Edited
by admin
on Sun Dec 18 19:39:25 UTC 2022
Record UNII
46627O600J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LEVODOPA
EMA EPAR   EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
LEVODOPA [JAN]
Common Name English
RYTARY COMPONENT LEVODOPA
Brand Name English
CARBILEV COMPONENT LEVODOPA
Common Name English
levodopa [INN]
Common Name English
LEVODOPA COMPONENT OF SINEMET
Common Name English
V-1512
Code English
LEVODOPA [WHO-IP]
Common Name English
LEVODOPA [ORANGE BOOK]
Common Name English
CORBILTA COMPONENT LEVODOPA
Brand Name English
LEVODOPA [EMA EPAR]
Common Name English
L-DOPA
Systematic Name English
LEVODOPA [USP-RS]
Common Name English
LEVODOPA COMPONENT OF DUOPA
Brand Name English
BENDOPA
Brand Name English
LEVODOPA COMPONENT OF STALEVO
Brand Name English
LEVODOPA [USAN]
Common Name English
LEVODOPA COMPONENT OF DOPASNAP
Common Name English
LEVODOPA [USP MONOGRAPH]
Common Name English
LEVODOPA/CARBIDOPA/ENTACAPONE ORION COMPONENT LEVODOPA
Brand Name English
LEVODOPA COMPONENT OF CORBILTA
Brand Name English
LEVODOPA [EP IMPURITY]
Common Name English
STALEVO COMPONENT LEVODOPA
Brand Name English
LEVODOPA COMPONENT OF PARCOPA
Common Name English
LARODOPA
Brand Name English
LEVODOPA COMPONENT OF LEVODOPA/CARBIDOPA/ENTACAPONE ORION
Brand Name English
IPX203 COMPONENT LEVODOPA
Common Name English
DOPAR
Brand Name English
DUOPA COMPONENT LEVODOPA
Brand Name English
PARCOPA COMPONENT LEVODOPA
Common Name English
LEVODOPA [HSDB]
Common Name English
LEVODOPA [EP MONOGRAPH]
Common Name English
IPX-203 COMPONENT LEVODOPA
Common Name English
LEVODOPA [MI]
Common Name English
LEVODOPA COMPONENT OF CARBILEV
Common Name English
DIHYDROXYPHENYLALANINE
Systematic Name English
NSC-118381
Code English
(-)-3-(3,4-DIHYDROXYPHENYL)-L-ALANINE
Systematic Name English
Levodopa [WHO-DD]
Common Name English
LEVODOPA COMPONENT OF DHIVY
Brand Name English
DHIVY COMPONENT LEVODOPA
Brand Name English
LEVODOPUM [WHO-IP LATIN]
Common Name English
LEVODOPA COMPONENT OF RYTARY
Brand Name English
L-TYROSINE, 3-HYDROXY-
Systematic Name English
DOPASNAP COMPONENT LEVODOPA
Common Name English
DOPA, L-
Systematic Name English
CVT-301
Common Name English
LEVODOPA [MART.]
Common Name English
INBRIJA
Brand Name English
LEVODOPA [VANDF]
Common Name English
Classification Tree Code System Code
WHO-VATC QN04BA03
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
DSLD 1198 (Number of products:24)
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
WHO-ESSENTIAL MEDICINES LIST 09 (LEV/CAR)
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
EMA ASSESSMENT REPORTS CORBILTA (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
EU-Orphan Drug EU/3/01/035
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
EMA ASSESSMENT REPORTS STALEVO (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
WHO-ATC N04BA01
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
EMA ASSESSMENT REPORTS CORBILTA (AUTHORIZED: NEURODEGENERATIVE DISEASES)
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
WHO-VATC QN04BA02
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
WHO-ATC N04BA03
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
WHO-VATC QN04BA01
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
LOINC 79577-3
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
NDF-RT N0000193220
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
LIVERTOX NBK548734
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
FDA ORPHAN DRUG 129499
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
NDF-RT N0000175754
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
WHO-ATC N04BA02
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
NCI_THESAURUS C66884
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
NDF-RT N0000175755
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
EMA ASSESSMENT REPORTS LEVODOPA/CARBIDOPA/ENTACAPONE ORION (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
EMA ASSESSMENT REPORTS CORBILTA (AUTHORIZED: NERVOUS SYSTEM DISEASES)
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
Code System Code Type Description
PUBCHEM
6047
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
WIKIPEDIA
L-DOPA
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
LACTMED
Levodopa
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
LEVODOPA
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY Description: A white or almost white, crystalline powder; odourless. Solubility: Soluble in 300 parts of water; practically insoluble in ethanol (~750 g/l) TS and ether R. Category: Antiparkinsonism drug. Storage: Levodopa should be kept in a tightly closed container.Definition: Levodopa contains not less than 98.5% and not more than 101.0% of C9H11NO4, calculated with reference to the dried substance.
MESH
D007980
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
DRUG CENTRAL
1567
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
NSC
118381
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
NCI_THESAURUS
C611
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
EVMPD
SUB08468MIG
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
EPA CompTox
DTXSID9023209
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
FDA UNII
46627O600J
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
ChEMBL
CHEMBL1009
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
DAILYMED
46627O600J
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
CHEBI
57504
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
HSDB
3348
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
CHEBI
15765
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
IUPHAR
3639
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
MERCK INDEX
M6786
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY Merck Index
INN
2651
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
ECHA (EC/EINECS)
200-445-2
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
CAS
59-92-7
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
RS_ITEM_NUM
1361009
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
DRUG BANK
DB01235
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY
RXCUI
6375
Created by admin on Sun Dec 18 19:39:28 UTC 2022 , Edited by admin on Sun Dec 18 19:39:28 UTC 2022
PRIMARY RxNorm
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
PARENT -> CONSTITUENT ALWAYS PRESENT
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
TARGET -> AGONIST
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
METABOLITE ACTIVE -> PRODRUG
METABOLITE ACTIVE -> PRODRUG
MAJOR
METABOLITE -> PARENT
When decarboxylation of levodopa is prevented by carbidopa, COMT becomes the major metabolizing enzyme for levodopa, catalyzing its metabolism to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD).
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 2.2
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY